Article info

Download PDFPDF

Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

Authors

  1. Correspondence to Professor Francis Berenbaum, Department of Rheumatology, Sorbonne Université, INSERM CRSA, AP-HP Hopital Saint Antoine, 184 rue du faubourg Saint-Antoine, Paris 75012, France; francis.berenbaum{at}aphp.fr
View Full Text

Citation

Berenbaum F, Blanco FJ, Guermazi A, et al
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

Publication history

  • Received September 10, 2019
  • Revised January 28, 2020
  • Accepted January 29, 2020
  • First published March 31, 2020.
Online issue publication 
May 20, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.